<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2021-6.1.2</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-2605</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>Поведенческие особенности пациентов с подагрой и их влияние на результаты уратоснижающей терапии</article-title><trans-title-group xml:lang="en"><trans-title>Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2538-2132</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чэн</surname><given-names>Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Chen</surname><given-names>J.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чэн Дзянчун – врач отделения ревматологии</p><p>610000, Вторая кольцевая дорога № 121, ул. Фунань, Циньян, г. Ченду, провинция Сычуань</p></bio><bio xml:lang="en"><p>Chen Jianchun – Doctor at the Rheumatology Department</p><p>121 West 2nd Ring Road, Funan str., Qingyang District, Chengdu city, Sichuan Province, China 610000</p></bio><email xlink:type="simple">cjc18030541834@163.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жу</surname><given-names>П.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhou</surname><given-names>P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жу Пан – врач отделения ревматологии</p><p>610000, Вторая кольцевая дорога № 121, ул. Фунань, Циньян, г. Ченду, провинция Сычуань</p></bio><bio xml:lang="en"><p>Zhou Pan – Doctor at the Rheumatology Department</p><p>121 West 2nd Ring Road, Funan str., Qingyang District, Chengdu city, Sichuan Province, China 610000</p></bio><email xlink:type="simple">464834845@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8560-1870</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тан</surname><given-names>В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tan</surname><given-names>W.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тан Вэй – врач отделения хирургии</p><p>610000, Вторая кольцевая дорога № 121, ул. Фунань, Циньян, г. Ченду, провинция Сычуань</p></bio><bio xml:lang="en"><p>Tan Wei – Doctor at the Surgical Department</p><p>121 West 2nd Ring Road, Funan str., Qingyang District, Chengdu city, Sichuan Province, China 610000</p></bio><email xlink:type="simple">tw18181420391@163.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5133-9472</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джен</surname><given-names>У.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheng</surname><given-names>M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Джен Уянь – кандидат медицинских наук, заведующая отделом научных разработок и инноваций</p><p>610000, Вторая кольцевая дорога № 121, ул. Фунань, Циньян, г. Ченду, провинция Сычуань</p></bio><bio xml:lang="en"><p>Zheng Wuyan – Cand. Sc. (Med.), Head of the Scientific Research Department</p><p>121 West 2nd Ring Road, Funan str., Qingyang District, Chengdu city, Sichuan Province, China 610000</p></bio><email xlink:type="simple">1642637460@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8027-5693</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ошмянская</surname><given-names>Н. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Oshmianska</surname><given-names>N. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ошмянская Наталья Юрьевна – кандидат медицинских наук, научный сотрудник отдела научных разработок и инноваций</p><p>610000, Вторая кольцевая дорога № 121, ул. Фунань, Циньян, г. Ченду, провинция Сычуань</p></bio><bio xml:lang="en"><p>Nataliia Y. Oshmianska – Research Officer at the Scientific Research Department</p><p>121 West 2nd Ring Road, Funan str., Qingyang District, Chengdu city, Sichuan Province, China 610000</p></bio><email xlink:type="simple">1283182076@qq.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ревматологический госпиталь г. Чэнду</institution></aff><aff xml:lang="en"><institution>Chengdu Rheumatism Hospital</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>04</month><year>2021</year></pub-date><volume>6</volume><issue>1</issue><fpage>13</fpage><lpage>17</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чэн Д., Жу П., Тан В., Джен У., Ошмянская Н.Ю., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Чэн Д., Жу П., Тан В., Джен У., Ошмянская Н.Ю.</copyright-holder><copyright-holder xml:lang="en">Chen J., Zhou P., Tan W., Zheng M., Oshmianska N.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/2605">https://www.actabiomedica.ru/jour/article/view/2605</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Подагра часто сопровождается гипертонией, ожирением и/или нарушением толерантности к глюкозе, которые нередко осложняют тяжёлое курение и нарушения питания, особенно у пациентов мужского пола.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: оценить поведенческие характеристики пациентов с подагрой, которые могут повлиять на результаты урикозурической терапии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Связь между поведенческими характеристиками и результатами уратоснижающей терапии была исследована у 74 пациентов с подагрой в ревматическом госпитале г. Чэнду. Результаты лечения оценивались с использованием содержания мочевой кислоты в сыворотке крови до и после лечения, по шкале болевых ощущений до и после лечения. Поведенческие характеристики за последние десять лет (статус курения, ежедневный объем питьевой воды и т. д.) были оценены с помощью ретроспективного опросника.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с подагрой, которые демонстрировали неудовлетворительный ответ на лечение, сывороточная мочевая кислота в начале лечения была значительно ниже (365,76 ± 163,06 мкмоль/л); эта тенденция была также была отмечена в группе с «медленным прогрессом», в то время как пациенты с более высоким содержанием мочевой кислоты в сыворотке крови до лечения демонстрировали заметно лучший ответ натерапию. В ходе дальнейшего анализа возраст отрицательно коррелировал с сывороточной мочевой кислотой (r = –0,328; р = 0,002) и коэффициентом клиренса мочевой кислоты (r = –0,299; р = 0,002). У пациентов с коэффициентом клиренса мочевой кислоты выше 40 % распространённость заболеваний почек (камни или дисфункция) была значительно ниже по сравнению с другими группами. Значимого влияния гипертонии, сахарного диабета, ожирения печени или гиперлипидемии на коэффициент клиренса мочевой кислоты отмечено не было (p &gt; 0,05).</p><p>Количество питьевой воды также влияло на клиренс мочевой кислоты в сыворотке крови. Большее количество пациентов в группе «быстрого прогресса» (40,0 % по сравнению с 30,44 и 25,0 %) имели тенденцию пить больше воды.</p></sec><sec><title>Заключение</title><p>Заключение. У большинства пациентов с подагрой уровни мочевой кислоты в сыворотке крови до лечения являлись надёжным предиктором удовлетворительного ответа на уратоснижающую терапию. Ответ на лечение (коэффициент клиренса мочевой кислоты в сыворотке крови) положительно коррелировал с гиперурикемией и употреблением достаточного количества воды, отрицательно – с длительным курением (более 10 лет) и возрастом.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Gout is frequently accompanied by hypertension, obesity, and/or impaired glucose tolerance, which are often complicated with heavy smoking and dietary violations, especially in male patients.</p></sec><sec><title>Objective</title><p>Objective. To determine the behavioral characteristics of gout patients that could impact the results of urate lowering therapy.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. The relationship between behavioral characteristics and results of urate lowering therapy were investigated in 74 male gout patients of Chengdu Rheumatism Hospital. The results of treatment were evaluated using serum uric acid contents before and after treatment, VAS pain score before and after treatment. Behavioral characteristics for the last ten years (smoking status, daily volume of drinking water, etc.) were accessed by means of retrospective survey.</p></sec><sec><title>Results</title><p>Results. In gout patients with poor treatment response, serum uric acid at the beginning of the treatment was already significantly lower (365.76 ± 163.06 μmol/L); this trend was also noted in a “slow progress” group, while patients with higher serum uric acid before treatment had notably better response to urate lowering therapy. During further analysis age negatively correlated with serum uric acid (r = –0.328; p = 0.002) and uric acid clearance ratio (r = –0.299; p = 0.002).</p><p>In patients with uric acid clearance ratio above 40 % the prevalence of kidney diseases (stones or dysfunction) was significantly lower compared to other groups. There was no significant influence of hypertension, diabetes mellitus, fatty liver or hyperlipidaemia on uric acid clearance ratio (p &gt; 0.05).</p><p>Amount of drinking water also influenced the serum uric acid clearance ratio. Bigger amount of patients in the “fast progress” group (40.0 % compared to 30.44 and 25.0 %) tended to drink more water.</p></sec><sec><title>Conclusion</title><p>Conclusion. In most gout patients, serum uric acid levels before treatment acted as the reliable predictor of good response to urate lowering therapy. Treatment response (serum uric acid clearance ratio) correlated positively with the hyperuricemia and drinking sufficient amounts of water, negatively – with prolonged smoking (more than 10 years) and age.</p></sec></trans-abstract><kwd-group xml:lang="en"><kwd>gout</kwd><kwd>urate lowering therapy</kwd><kwd>smoking</kwd><kwd>uric acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16(7): 380-390. doi: 10.1038/s41584020-0441-1</mixed-citation><mixed-citation xml:lang="en">Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16(7): 380-390. doi: 10.1038/s41584020-0441-1</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mattiuzzi C, Lippi G. Recent updates on worldwide gout epidemiology. Clin Rheumatol. 2020; 39(4): 1061-1063. doi: 10.1007/ s10067-019-04868-9</mixed-citation><mixed-citation xml:lang="en">Mattiuzzi C, Lippi G. Recent updates on worldwide gout epidemiology. Clin Rheumatol. 2020; 39(4): 1061-1063. doi: 10.1007/ s10067-019-04868-9</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mu Z, Wang W, Wang J, Lv W, Chen Y, Wang F, et al. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: A post-hoc analysis of a multicenter randomized trial. Clin Rheumatol. 2019; 38(12): 3511-3519. doi: 10.1007/s10067-019-04737-5</mixed-citation><mixed-citation xml:lang="en">Mu Z, Wang W, Wang J, Lv W, Chen Y, Wang F, et al. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: A post-hoc analysis of a multicenter randomized trial. Clin Rheumatol. 2019; 38(12): 3511-3519. doi: 10.1007/s10067-019-04737-5</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifi tions for gout. Arthritis Res Ther. 2006; 8(Suppl 1): S2. doi: 10.1186/ar1907</mixed-citation><mixed-citation xml:lang="en">Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifi tions for gout. Arthritis Res Ther. 2006; 8(Suppl 1): S2. doi: 10.1186/ar1907</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Graham GG, Stocker SL, Kannangara DR, Day RO. Predicting response or non-response to urate-lowering therapy in patients with gout. Curr Rheumatol Rep. 2018; 20(8): 47. doi: 10.1007/ s11926-018-0760-2</mixed-citation><mixed-citation xml:lang="en">Graham GG, Stocker SL, Kannangara DR, Day RO. Predicting response or non-response to urate-lowering therapy in patients with gout. Curr Rheumatol Rep. 2018; 20(8): 47. doi: 10.1007/ s11926-018-0760-2</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez-Lozada LG. The pathophysiology of uric acid on renal diseases. Contrib Nephrol. 2018; 192: 17-24. doi: 10.1159/000484274</mixed-citation><mixed-citation xml:lang="en">Sánchez-Lozada LG. The pathophysiology of uric acid on renal diseases. Contrib Nephrol. 2018; 192: 17-24. doi: 10.1159/000484274</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016; 81(2): 277-289. doi: 10.1111/bcp.12799</mixed-citation><mixed-citation xml:lang="en">Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016; 81(2): 277-289. doi: 10.1111/bcp.12799</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Goldfarb DS. Review: Thiazide, citrate, or allopurinol reduces recurrence after ≥ 2 kidney stone episodes. Ann Intern Med. 2013; 159(2): JC12. doi: 10.7326/0003-4819-159-2-201307160-02012</mixed-citation><mixed-citation xml:lang="en">Goldfarb DS. Review: Thiazide, citrate, or allopurinol reduces recurrence after ≥ 2 kidney stone episodes. Ann Intern Med. 2013; 159(2): JC12. doi: 10.7326/0003-4819-159-2-201307160-02012</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther. 2010; 12(2): R63. doi: 10.1186/ar2978</mixed-citation><mixed-citation xml:lang="en">Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther. 2010; 12(2): R63. doi: 10.1186/ar2978</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: Results from the Framingham Heart Study original cohort. Rheumatology. 2015; 54(1): 91-95. doi: 10.1093/rheumatology/keu304</mixed-citation><mixed-citation xml:lang="en">Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: Results from the Framingham Heart Study original cohort. Rheumatology. 2015; 54(1): 91-95. doi: 10.1093/rheumatology/keu304</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Teng GG, Pan A, Yuan JM, Koh WP. Cigarette smoking and the risk of incident gout in a prospective cohort study. Arthritis Care Res. 2016; 68(8): 1135-1142. doi: 10.1002/acr.22821</mixed-citation><mixed-citation xml:lang="en">Teng GG, Pan A, Yuan JM, Koh WP. Cigarette smoking and the risk of incident gout in a prospective cohort study. Arthritis Care Res. 2016; 68(8): 1135-1142. doi: 10.1002/acr.22821</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fanning N, Merriman TR, Dalbeth N, Stamp LK. An association of smoking with serum urate and gout: A health paradox. Semin Arthritis Rheum. 2018; 47(6): 825-842. doi: 10.1016/j.semarthrit.2017.11.004</mixed-citation><mixed-citation xml:lang="en">Fanning N, Merriman TR, Dalbeth N, Stamp LK. An association of smoking with serum urate and gout: A health paradox. Semin Arthritis Rheum. 2018; 47(6): 825-842. doi: 10.1016/j.semarthrit.2017.11.004</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hisatome I, Ohtahara A, Hamada T, Ogino K. Development of Guideline for the management of hyperuricemia and gout in Japan 3rd edition. Gout and Nucleic Acid Metabolism. 2018; 42(2): 147-156. doi: 10.6032/gnam.42.147</mixed-citation><mixed-citation xml:lang="en">Hisatome I, Ohtahara A, Hamada T, Ogino K. Development of Guideline for the management of hyperuricemia and gout in Japan 3rd edition. Gout and Nucleic Acid Metabolism. 2018; 42(2): 147-156. doi: 10.6032/gnam.42.147</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
